Targeting mitophagy in Parkinson's disease
EH Clark, AV de la Torre, T Hoshikawa… - Journal of Biological …, 2021 - ASBMB
The genetics and pathophysiology of Parkinson's disease (PD) strongly implicate
mitochondria in disease aetiology. Elegant studies over the last two decades have …
mitochondria in disease aetiology. Elegant studies over the last two decades have …
Targeting mitochondrial impairment in Parkinson's disease: challenges and opportunities
The underlying pathophysiology of Parkinson's disease is complex, but mitochondrial
dysfunction has an established and prominent role. This is supported by an already large …
dysfunction has an established and prominent role. This is supported by an already large …
Synaptic vesicle glycoprotein 2A: features and functions
In recent years, the field of neuroimaging dramatically moved forward by means of the
expeditious development of specific radioligands of novel targets. Among these targets, the …
expeditious development of specific radioligands of novel targets. Among these targets, the …
Imaging of synaptic density in neurodegenerative disorders
PET technology has produced many radiopharmaceuticals that target specific brain proteins
and other measures of brain function. Recently, a new approach has emerged to image …
and other measures of brain function. Recently, a new approach has emerged to image …
Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Parkinson's disease
Parkinson's disease (PD) is a debilitating neurological disorder characterized by the
impairment of the motor system, resulting in symptoms such as resting tremor, cogwheel …
impairment of the motor system, resulting in symptoms such as resting tremor, cogwheel …
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [11C]UCB‐J PET Imaging Study
ABSTRACT Background Patients with Parkinson's disease (PD) often develop dementia, but
the underlying substrate is incompletely understood. Generalized synaptic degeneration …
the underlying substrate is incompletely understood. Generalized synaptic degeneration …
[HTML][HTML] PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats
MB Thomsen, SA Ferreira, AC Schacht… - Neurobiology of …, 2021 - Elsevier
Abstract Alpha-synuclein (a-syn) can aggregate and form toxic oligomers and insoluble
fibrils which are the main component of Lewy bodies. Intra-neuronal Lewy bodies are a …
fibrils which are the main component of Lewy bodies. Intra-neuronal Lewy bodies are a …
Comprehensive map** of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground …
Synaptic dysfunction and loss are central to neurodegenerative diseases and correlate with
cognitive decline. Synaptic Vesicle Protein 2A (SV2A) is a promising PET-imaging target for …
cognitive decline. Synaptic Vesicle Protein 2A (SV2A) is a promising PET-imaging target for …
Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson's disease and dementia with Lewy bodies
I Frigerio, MMA Bouwman, RT Noordermeer… - Acta Neuropathologica …, 2024 - Springer
Regional differences in synaptic degeneration may underlie differences in clinical
presentation and neuropathological disease progression in Parkinson's Disease (PD) and …
presentation and neuropathological disease progression in Parkinson's Disease (PD) and …
How should we be using biomarkers in trials of disease modification in Parkinson's disease?
The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …